Evidence map›Paper›PMID 37830583›Full record

ArticleCells2023

MicroRNA-30d-5p-A Potential New Therapeutic Target for Prevention of Ischemic Cardiomyopathy after Myocardial Infarction.

Elke Boxhammer, Vera Paar, Bernhard Wernly, Attila Kiss, Moritz Mirna, Achim Aigner, Eylem Acar, Simon Watzinger, Bruno K Podesser, Roland Zauner and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. The Phoenix Heart-PICSO and the Rebirth of Embryonic Life in the Ischemic Myocardium.Journal of cardiovascular development and disease · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Impact of microRNAs on cardiovascular diseases and aging.The Journal of international medical research · 2024
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Elke BoxhammerInternal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0002-6589-3853
Vera PaarInternal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0002-4743-3220
Bernhard WernlyDepartment of Internal Medicine, General Hospital Oberndorf, Teaching Hospital of the Paracelsus Medical University, 5110 Oberndorf, Austria.ORCID 0000-0003-4024-0220
Attila KissLudwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0003-4652-1998
Moritz MirnaInternal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0001-5679-4872
Achim AignerRudolf Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig University, 04107 Leipzig, Germany.ORCID 0000-0002-2778-6256
Eylem AcarLudwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria.
Simon WatzingerLudwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria.
Bruno K PodesserLudwig Boltzmann Cluster for Cardiovascular Research, Center for Biomedical Research and Translational Surgery, Medical University Vienna, 1090 Vienna, Austria.ORCID 0000-0002-4641-7202
Roland ZaunerDermatology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0003-0590-3877
Verena WallyDermatology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.ORCID 0000-0001-8705-3890
Michael AblingerDermatology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Matthias HacklTAmiRNA GmbH, Muthgasse 18, 1110 Vienna, Austria.
Uta C HoppeInternal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Michael LichtenauerInternal Medicine II, Department of Cardiology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
Paracelsus Medical University · ATLudwig Boltzmann Institute for Cardiovascular Research · ATLeipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background and Objective: MicroRNAs (miRs) are biomarkers for assessing the extent of cardiac remodeling after myocardial infarction (MI) and important predictors of clinical outcome in heart failure. Overexpression of miR-30d-5p appears to have a cardioprotective effect. The aim of the present study was to demonstrate whether miR-30d-5p could be used as a potential therapeutic target to improve post-MI adverse remodeling. (2) Methods and Results: MiR profiling was performed by next-generation sequencing to assess different expression patterns in ischemic vs. healthy myocardium in a rat model of MI. MiR-30d-5p was significantly downregulated (

Indexed as

CardiomyopathiesMicroRNAsMyocardial InfarctionMyocardial IschemiaAnimalsEndothelial CellsHumansRatsRNA, Small InterferingTumor Suppressor Protein p53MicroRNAsRNA, Small InterferingTumor Suppressor Protein p53cardioprotectionischemic cardiomyopathymiR-30d-5pmyocardial infarction

Identifiers

PMID37830583
PMCPMC10571870
OpenAlexW4387120944

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.